Evidence map›Paper›PMID 34733788›Full record

ArticleFrontiers in oncology2021

ARV-825 Demonstrates Antitumor Activity in Gastric Cancer

Xinmei Liao, Xiaoqing Qian, Zimu Zhang, Yanfang Tao, Zhiheng Li, Qian Zhang, Hui Liang, Xiaolu Li, Yi Xie, Ran Zhuo and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs.Angewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Viability ofmicroPublication biology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. PROTACs in gastrointestinal cancers.Molecular therapy oncolytics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Xinmei LiaoInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Xiaoqing QianInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Zimu ZhangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Yanfang TaoInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Zhiheng LiInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Qian ZhangInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Hui LiangInstitute of Nanomedicine, National Engineering Research Centre for Nanotechnology, Shanghai, China.
Xiaolu LiInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Yi XieInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Ran ZhuoInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Yanling ChenInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
You JiangInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Haibo CaoInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Jiaqi NiuInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Cuili XueInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Jian NiInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Jian PanInstitute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Daxiang CuiInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Soochow University · CNShanghai Jiao Tong University · CNNational Engineering Research Center for Nanotechnology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSuppression of bromodomain and extra terminal (BET) proteins has a bright prospect to treat MYC-driven tumors. Bromodomain containing 4 (BRD4) is one of the BET proteins. ARV-825, consisting of a BRD4 inhibitor conjugated with a cereblon ligand using proteolysis-targeting chimera (PROTAC) technology, was proven to decrease the tumor growth effectively and continuously. Nevertheless, the efficacy and mechanisms of ARV-825 in gastric cancer are still poorly understood.

methodsCell counting kit 8 assay, lentivirus infection, Western blotting analysis, Annexin V/propidium iodide (PI) staining, RNA sequencing, a xenograft model, and immunohistochemistry were used to assess the efficacy of ARV-825 in cell level and animal model.

resultsThe messenger RNA (mRNA) expression of

conclusionsHigh mRNA expression of

Indexed as

ARV-825BRD4c-Mycgastric cancerPLK1

Identifiers

PMID34733788
PMCPMC8559897
OpenAlexW3207656135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.